SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is seeing heightened volatility as markets digest TSMC's comments regarding the high cost of next-generation High-NA EUV machinery, leading some investors to debate the timeline for adoption versus the company's entrenched lithography monopoly. Despite the pullback, the community remains intensely focused on the stock's role as the indispensable bottleneck for AI infrastructure, with many traders framing the price dip as a long-term accumulation opportunity.

Based is a financial superapp built on Hyperliquid that lets users trade crypto, equities, and commodities from a single interface, fund accounts directly from bank accounts or credit cards, and spend balances at over 100 million merchants worldwide using a Visa Platinum card that converts at the point of sale with no separate off-ramp required. The platform operates across web, iOS, Android, and desktop with one account, and includes features like curated Launchpools for early project access and AI-native wallets for autonomous trading and risk monitoring.

Based Token

BASED is currently seeing heightened community activity and volatility as traders speculate on its potential within the broader Base chain ecosystem. The sentiment is polarized, with some investors betting on its utility-driven app model while others express caution regarding price swings and the speculative nature of the project.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following the announcement of an upcoming FDA advisory committee meeting for Deramiocel and the release of positive five-year clinical data. The community is actively debating whether this committee serves as a pathway for broader regulatory approval or represents a source of renewed uncertainty regarding the path to commercialization.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is seeing heightened community discourse as investors balance optimism over its pivot toward AI-integrated network infrastructure with frustration regarding recent downward price volatility and institutional rotation. While the stock continues to attract interest based on its photonics moat and potential as a national security play in the 5G/6G space, traders are actively debating whether current support levels represent a strategic accumulation opportunity ahead of upcoming quarterly earnings or a deeper technical correction.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent double-digit decline represents a structural breakdown or a significant accumulation opportunity following a guidance adjustment and accelerated share repurchase program. While some market participants express frustration over persistent selling pressure, many community members are aggressively loading shares, viewing the current valuation as disconnected from long-term fundamentals and potential M&A catalysts.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is experiencing intense volatility driven by cascading stop-loss liquidations and sector-wide sentiment shifts, while long-term investors remain focused on the company's strong, sold-out backlog for semiconductor equipment. The community is actively debating whether this pullback represents a fundamental turning point or a temporary liquidity reset in an otherwise durable AI-infrastructure supercycle.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus Energy is gaining traction as investors focus on its critical role in the U.S. nuclear fuel supply chain, particularly following its recent S&P SmallCap 600 inclusion and significant Department of Energy contract wins. The community remains highly focused on the company's unique position as a domestic supplier of HALEU and its long-term strategic importance in powering the next generation of small modular reactors.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate Technology and the broader memory sector are trending as investors weigh the impact of potential production capacity constraints against sustained, AI-driven demand. Community discourse is heavily split between bulls focused on tight supply and favorable long-term fundamentals, and bears concerned that high-flying valuations reflect an overextended cycle prone to volatility.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors debate the disconnect between its real-world retail presence in major stores and the token's recent market performance. While some community members remain bullish on its brand-driven utility, others are frustrated by ongoing price volatility and are actively weighing the risks of accumulating during this consolidation phase.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is in the spotlight as investors await a regulatory update regarding its BLA for the Hunter syndrome treatment, with the stock experiencing heightened volatility amid community anxiety over potential clinical holds and regulatory outcomes. The community remains focused on the company's long-term pipeline potential, particularly the RGX-202 Duchenne muscular dystrophy program and the AbbVie partnership, while debating the impact of shifting FDA oversight on rare disease approvals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
